Scientific Reports (Mar 2023)

Ex vivo expansion of circulating tumour cells (CTCs)

  • Bashir M. Mohamed,
  • Mark P. Ward,
  • Mark Bates,
  • Cathy D. Spillane,
  • Tanya Kelly,
  • Cara Martin,
  • Michael Gallagher,
  • Sheena Heffernan,
  • Lucy Norris,
  • John Kennedy,
  • Feras Abu Saadeh,
  • Noreen Gleeson,
  • Doug A. Brooks,
  • Robert D. Brooks,
  • Stavros Selemidis,
  • Sharon O’Toole,
  • John J. O’Leary

DOI
https://doi.org/10.1038/s41598-023-30733-6
Journal volume & issue
Vol. 13, no. 1
pp. 1 – 13

Abstract

Read online

Abstract Circulating tumour cells (CTCs) are a critical intermediate step in the process of cancer metastasis. The reliability of CTC isolation/purification has limited both the potential to report on metastatic progression and the development of CTCs as targets for therapeutic intervention. Here we report a new methodology, which optimises the culture conditions for CTCs using primary cancer cells as a model system. We exploited the known biology that CTCs thrive in hypoxic conditions, with their survival and proliferation being reliant on the activation of hypoxia-inducible factor 1 alpha (HIF-1α). We isolated epithelial-like and quasi-mesenchymal CTC phenotypes from the blood of a cancer patient and successfully cultured these cells for more than 8 weeks. The presence of CTC clusters was required to establish and maintain long-term cultures. This novel methodology for the long-term culture of CTCs will aid in the development of downstream applications, including CTC theranostics.